Related Experiment Video
Updated: Dec 1, 2025
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and
R A Tuty Kuswardhani1, Joshua Henrina2, Raymond Pranata3
1Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Teaching Hospital, Denpasar- Bali, Indonesia.
Insights
The Charlson Comorbidity Index (CCI) effectively stratifies COVID-19 patient risk. Higher CCI scores correlate with increased mortality and severe outcomes in hospitalized patients.
Area of Science:
- Medical research
- Epidemiology
- Public health
Background:
- COVID-19 disproportionately impacts patients with comorbidities.
- Accurate comorbidity assessment is crucial for risk stratification upon hospital admission.
- The Charlson Comorbidity Index (CCI) is a validated tool for predicting mortality risk from comorbid diseases.
Purpose of the Study:
- To systematically review and meta-analyze the association between CCI scores and COVID-19 patient outcomes.
- To evaluate the prognostic value of CCI in predicting mortality and composite poor outcomes in hospitalized COVID-19 patients.
Main Methods:
- Systematic review and meta-analysis.
- Inclusion of studies assessing CCI scores and a composite of poor outcomes in COVID-19 patients.
Main Results:
- A CCI score of 1-2 and ≥3 was associated with increased mortality and composite poor outcomes compared to a CCI of 0.
- Each point increase in CCI score elevated mortality risk by 16%.
- Higher mean CCI scores significantly correlated with mortality and disease severity.
Conclusions:
- The CCI is a valuable tool for risk stratification in hospitalized COVID-19 patients.
- Utilizing CCI can aid in identifying high-risk individuals for targeted interventions.
Background And Aims:
The ongoing COVID-19 pandemic is disproportionately affecting patients with comorbidities. Therefore, thorough comorbidities assessment can help establish risk stratification of patients with COVID-19, upon hospital admission. Charlson Comorbidity Index (CCI) is a validated, simple, and readily applicable method of estimating the risk of death from comorbid disease and has been widely used as a predictor of long-term prognosis and survival.
Methods:
We performed a systematic review and meta-analysis of CCI score and a composite of poor outcomes through several databases.
Results:
Compared to a CCI score of 0, a CCI score of 1-2 and CCI score of ≥3 was prognostically associated with mortality and associated with a composite of poor outcomes. Per point increase of CCI score also increased mortality risk by 16%. Moreover, a higher mean CCI score also significantly associated with mortality and disease severity.
Conclusion:
CCI score should be utilized for risk stratifications of hospitalized COVID-19 patients.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:30Pneumonia III: Complications and Assessment
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies